Can a new triple therapy outsmart resistant myeloma?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older (or the minimum age of consent under local rules, if that is 18 or over) * A diagnosis of multiple myeloma that has either come back (relapsed) or did not respond (refractory) after the most recent treatment * Myeloma that can be measured using standard study tests (blood and/or urine tests) * Between 1 and 4 previous courses (lines) of myeloma treatment, which must have included both a treatment that targets CD38 (such as daratumumab or isatuximab) and lenalidomide * Well enough to carry out daily activities with little or no help (Eastern Cooperative Oncology Group \[ECOG\] performance status of 0 to 2) * Suitable blood test results and adequate kidney and liver function * Willingness to use highly effective contraceptive measures (if sexually active) with all sexual partners Exclusion Criteria: * Recent anticancer treatment before starting study treatment: any experimental medicine, chemotherapy, immunotherapy or other anticancer treatment within 14 days or 5 half-lives (whichever is shorter), or certain antibody-based treatments within longer set periods * Previous treatment with a medicine that works in the same way as inobrodib (a p300/CBP bromodomain inhibitor) * Myeloma that has already stopped responding to pomalidomide (pomalidomide-refractory), unless only short-term pomalidomide was used and the study doctor confirms the person still meets the study rules * Unable to receive at least one of the standard treatment options offered in the study, or unable/unwilling to follow the requirements for at least one of those options * Taking medicines, herbal supplements or foods (for example, strong CYP3A4 inducers or inhibitors) that would interfere with the study treatment * Major surgery within 4 weeks before the first dose of study treatment * A live vaccine within 4 weeks before study treatment * A recent stem cell transplant, or ongoing transplant-related problems such as graft-versus-host disease * Myeloma affecting the brain, spinal fluid or spinal cord, or ongoing pressure on the spinal cord * Another active cancer (progressing or needing a change in treatment) in the last 24 months, other than multiple myeloma, apart from certain low-risk or fully treated cancers * Serious or uncontrolled medical problems, such as uncontrolled heart, lung, liver, bleeding or diabetes conditions, uncontrolled high blood pressure, or a heart-rhythm problem (including QT prolongation) * An active or uncontrolled infection, including certain cases of HIV, hepatitis B or hepatitis C * Digestive problems that could stop the study medicines being swallowed or properly absorbed * Pregnant or breastfeeding, or planning to become pregnant, father a child or donate sperm during treatment or the required post-treatment period * Any illness or medical history that could affect safety, the ability to follow study requirements, or the interpretation of study results